2yfx: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{STRUCTURE_2yfx| PDB=2yfx | SCENE= }} | {{STRUCTURE_2yfx| PDB=2yfx | SCENE= }} | ||
=== | ===Structure of L1196M Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib=== | ||
{{ABSTRACT_PUBMED_24432909}} | |||
==About this Structure== | ==About this Structure== | ||
[[2yfx]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/ | [[2yfx]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2YFX OCA]. | ||
[[Category: | |||
==See Also== | |||
*[[Tyrosine kinase|Tyrosine kinase]] | |||
==Reference== | |||
<ref group="xtra">PMID:024432909</ref><references group="xtra"/><references/> | |||
[[Category: Human]] | |||
[[Category: Receptor protein-tyrosine kinase]] | [[Category: Receptor protein-tyrosine kinase]] | ||
[[Category: Brooun, A.]] | [[Category: Brooun, A.]] | ||
[[Category: Deng, Y.]] | [[Category: Deng, Y.]] | ||
[[Category: Liu, W.]] | [[Category: Liu, W.]] | ||
[[Category: | [[Category: McTigue, M.]] | ||
[[Category: Nucleotide-binding]] | [[Category: Nucleotide-binding]] | ||
[[Category: Receptor]] | [[Category: Receptor]] | ||
[[Category: Transferase]] | [[Category: Transferase]] | ||
Revision as of 08:52, 19 March 2014
Structure of L1196M Mutant Anaplastic Lymphoma Kinase in Complex with Crizotinib
Template:ABSTRACT PUBMED 24432909
About this Structure
2yfx is a 1 chain structure with sequence from Human. Full crystallographic information is available from OCA.
See Also
Reference
- Huang Q, Johnson TW, Bailey S, Brooun A, Bunker KD, Burke BJ, Collins MR, Cook A, Cui JJ, Dack KN, Deal JG, Deng YL, Dinh DM, Engstrom LD, He M, Hoffman J, Hoffman RL, Shen H, Johnson P, Kania RS, Lam H, Lam JL, Le P, Li Q, Lingardo L, Liu W, West Lu M, McTigue MA, Palmer CL, Richardson PF, Sach NW, Smeal T, Smith GL, Stewart AE, Timofeevski SL, Tsaparikos K, Wang H, Zhu H, Zhu J, Zou HY, Edwards M. The design of potent and selective inhibitors to overcome clinical ALK mutations resistant to crizotinib. J Med Chem. 2014 Jan 16. PMID:24432909 doi:https://dx.doi.org/10.1021/jm401805h
